Teleflex is no longer the diversified hospital catalog it was a year ago. The Wayne, Pennsylvania device maker is mid-transformation into a narrower vascular, interventional, and surgical franchise, and the June quarter is the first full print under Jason Weidman, the Medtronic veteran who took the chief executive seat in early June. Reported continuing sales reached $570 million because last year's comparable still lacked a full Biotronik Vascular Intervention contribution. The more honest read is the pro forma constant-currency gain near five percent, which already sits below the growth rate management had been advertising for the year.
That gap is the entire investment debate. Vascular and Surgical carried the quarter with high-single-digit gains in hemostats, central access, ligation clips, and staplers. Interventional, the category that was supposed to justify last summer's euro-denominated Biotronik purchase, slipped about one percent on a comparable basis as order-to-cash, distributor, and sales-force conversion ran long. Management cut the full-year comparable growth outlook and raised adjusted earnings guidance in the same breath. The raise cites a completed $250 million share repurchase and a lower interest bill after OEM sale proceeds retired the $700 million Term Loan A-two.
The market is being asked to treat this year as a transition whose earnings power is being manufactured above the operating line by capital return while the cath-lab engine is rebuilt. The remaining Acute Care and Interventional Urology sale is still open. Shares recently changed hands near $129, a capitalization near $5.5 billion on the mid-August share count. The question the next two quarters resolve is whether Interventional stops being a drag so the cleaned-up company can look like a mid-single-digit grower with a twenty three percent steady-state margin, or whether the earnings raise is just a smaller share count sitting on a stalled franchise.